Molecular imaging and therapy developer NeuroSurvival Technologies (NST) of Petach-Tikva, Israel, has completed $13.3 million in financing and changed its name.
NST now will be known as Aposense, the same name as the company's molecular imaging agent for programmed cell death.
The Aposense agent, currently under development, is designed to detect signs of apoptosis, a genetically controlled process of cell death that is associated with most medical disorders. Potential clinical applications include oncology, neurology, and cardiology.
Related Reading
IBA, NeuroSurvival Technologies partner, August 14, 2008
NST is cleared for Aposense trials, July 25, 2008
Copyright © 2008 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
